Full-Time

HEOR Director

Confirmed live in the last 24 hours

Alector

Alector

201-500 employees

Develops therapies for neurodegenerative diseases

Biotechnology
Healthcare

Compensation Overview

$261k - $282kAnnually

Senior

Remote in USA

Category
Public Health
Biology & Biotech
Requirements
  • Advanced degree (PhD, PharmD, MD, or Master’s) in Health Economics, Epidemiology, Public Health, or a related field.
  • Minimum of 5 years of experience in HEOR, preferably within the pharmaceutical or biotechnology industry.
  • Proven track record of developing and implementing HEOR strategies that support product launches and market access.
  • Strong understanding of payer perspectives and the healthcare reimbursement landscape.
  • Excellent communication and presentation skills.
  • Experience working in neurology and rare diseases is highly desirable.
  • Launch experience in neurology and rare disease.
Responsibilities
  • Build the HEOR strategy and plan for each program including design and execution of HEOR studies, including, literature reviews, burden of illness analyses, budget impact models, cost-effectiveness models, patient-reported outcomes, and real-world evidence.
  • Effective presentation of research findings to internal and external stakeholders.
  • Work collaboratively with alliance partners to ensure the success of our programs.
  • Collaborate cross-functionally with medical affairs, marketing/commercial, regulatory, market access, and clinical teams to ensure evidence and outcomes data are integrated into clinical studies, commercialization plans and payer engagements.
  • Develop and communicate HEOR data of varying levels of complexity to formulary and healthcare policy decision-makers in compliance with company policies.
  • Develop the global value dossier, AMCP dossier, and value messages for payer interactions.
  • Stay up to date with advancements in health economics methodologies and best practices.
  • Identify and work with regional and national HEOR & RWE experts and organizations.
  • Closely monitor national and regional changes in healthcare policy and the payer environment and communicate the impact on the company.

Alector develops therapies aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's. The company focuses on research and development of new drug candidates by utilizing knowledge from immunology, neurology, and human genetics. Their approach involves conducting early-stage clinical trials to gather specific data about diseases, which helps improve the chances of success for their treatments. Alector differentiates itself from competitors by emphasizing the body's natural healing processes in their drug development. The company's goal is to create effective treatments for conditions that currently have limited options, thereby addressing significant medical needs in the healthcare sector.

Company Stage

IPO

Total Funding

$189.2M

Headquarters

San Francisco, California

Founded

2013

Growth & Insights
Headcount

6 month growth

0%

1 year growth

1%

2 year growth

-8%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $75 million financing round strengthens Alector's financial position, enabling further R&D efforts.
  • FDA Breakthrough Designation for latozinemab, developed in collaboration with GSK, highlights the potential impact of their therapies.
  • The appointment of experienced leaders from companies like Genentech and Kura Oncology bolsters Alector's executive team, enhancing strategic direction and operational execution.

What critics are saying

  • The biopharmaceutical industry is highly competitive and capital-intensive, requiring continuous investment to sustain R&D efforts.
  • Dependence on successful clinical trial outcomes and regulatory approvals poses significant risks to the commercialization of their therapies.

What makes Alector unique

  • Alector leverages a unique combination of immunology, neurology, and genetics to develop therapies, setting it apart from competitors who may focus on just one of these areas.
  • Their strategic partnerships with major pharmaceutical companies like GSK and AbbVie enhance their R&D capabilities and accelerate the commercialization of their therapies.
  • Alector's focus on early-stage clinical trials and rapid data collection increases the probability of success for their therapeutic candidates.

Help us improve and share your feedback! Did you find this helpful?